Exact Sciences Corp
—- Market cap
- —
- Debt
- +$2.85B
- Cash
- −$964.71M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $11.95B · View financials
Decision snapshot: EXAS stock price vs AIT: inconclusive — current versus $40.92 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AIT's multiple
Implied fair value · at EXAS's multiple
Needs EXAS P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXAS FY 2025 (ended Dec 31, 2025) · AIT FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 98% equity / 2% debt
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
EXACT SCIENCES CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
APPLIED INDUSTRIAL TECHNOLOGIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.19x
0.14x
Net debt / EBITDA
Leverage against operating earnings
35.68x
—
Cash and equivalents
Liquid reserves on the balance sheet
$964.71M
—
Total debt
Interest-bearing obligations outstanding
$2.85B
$262.30M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
OPKO HEALTH, INC.
EXAS vs OPK
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
W.W. GRAINGER, INC.
EXAS vs GWW
MSC INDUSTRIAL DIRECT CO INC
EXAS vs MSM
FASTENAL CO
EXAS vs FAST
GENUINE PARTS CO
EXAS vs GPC
Parker-Hannifin Corp
EXAS vs PH
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.